Skip to content

Abbott ABT Indefinite-Lived Intangible Assets

Indefinite-Lived Intangible Assets at other companies

Boston Scientific logo
Boston ScientificBSX
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Revenue$11.2B+7.8%
Gross profit$6.3B+6.5%
Operating income$1.3B-20.6%
Net income$1.1B-18.7%
EPS (diluted)$0.61-19.7%

Balance sheet

See full
Cash & equivalents$6.8B+4.2%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%
Free cash flow$916.0M-1.8%

Valuation

See full
Market cap$154.15B-22.5%
Enterprise value$181.39B-13.1%
P/E24.6×+9.8×
P/S3.4×-1.3×

Profitability

See full
Gross margin56.3%+0.4pp
Operating margin17.1%+0.2pp
Net margin13.9%-18.0pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's indefinite-lived intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's indefinite-lived intangible assets?
Abbott (ABT) reported indefinite-lived intangible assets of $1.2B in Q1 2026.
How has Abbott's indefinite-lived intangible assets changed year-over-year?
Abbott's indefinite-lived intangible assets increased by 53.1% year-over-year, from $784M to $1.2B.
What is the long-term trend for Abbott's indefinite-lived intangible assets?
Over 4 years (2021 to 2025), Abbott's indefinite-lived intangible assets has grown at a 6.9% compound annual growth rate (CAGR), from $919M to $1.2B.